Bookmark and Share
Home >> Business
Hitting cancer where it hurts: Mixed opioid somatostatin ligands as tomorrow's anti-cancer targe
 Added: 02/25/2002 -

Target identification specialists at LeadDiscovery, the drug discovery, development and transfer consultants, have recently focused on a series of compounds that fits just this profile. Human breast cancers have long been known to express somatostatin SSTR2 receptors and indeed this has been exploited by companies looking for improved way . . .     read more >>



  

  ReutersABCAP BBCCBCCBSMSNBCNBCNPRNYTSCIUPIUSAWorld RSS Feed
© prFocus.com
Press Release Forum
Death Psychic! - Shape Test - BigFibs - Easy Recipes - PuzzleGrid - Divorce Help - US Cycle Rally - Who's Pregnant?
Flash Arcade - Crazy Pictures! - Win Child Custody - Supervised Visitation - HeMale Or SheMale? - FunStars!